Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
€ 0.37
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.
Data is available to registered users only
Buy
Sell